Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

WEDNESDAY, SEPTEMBER 2, 2026 — EVENING WRAP

Wall Street snaps a three-session losing streak while Dell lifts its annual artificial intelligence server target by 14 billion dollars

Two things separated Wednesday, September 2, 2026 from the three sessions before it. A company raised its own numbers rather than defending them, and the equity indices stopped falling even though the barrel and the long end of the curve carried on rising. A note on the readings below, because it matters: this edition is written while the New York session is still open, so no settled close exists for September 2 and none is claimed here. Every level attributed to Marketstack is a settled close for Tuesday, September 1, 2026, the most recent settlement the provider carries; every level for September 2 is an intraday reading attributed to the source that published it.

THE SESSION SO FAR×
  • The three major American indices were higher in Wednesday afternoon trade and on course to break a three-session losing run. The S&P 500 was up about 0.4 percent around 7,663 points, the Nasdaq Composite about 0.3 percent, and the Dow Jones Industrial Average was ahead roughly 233 points, or 0.4 percent. These are intraday readings, not closes.MARKETS
  • Leadership sat with technology and banks. Meta was up around 2.5 percent and Wells Fargo about 3 percent on the same intraday coverage, and midday reporting described momentum rotating toward small caps and cyclicals.MARKETS
  • What did not change is the backdrop. The rally happened with crude at a six-week high and with the ten-year yield printing a new high for the move, which is the opposite of the conditions that usually produce a bounce in long-duration equity.MARKETS
  • For reference, the settled Marketstack closes for Tuesday, September 1 were $SPY at 761.78, $QQQ at 707.64, $DIA at 527.75 and $IWM at 290.57. Those remain the last settlements available from the provider at the time of writing.MARKETS
ADP: THE LABOUR MARKET SLOWS INTO FRIDAY×
  • The ADP National Employment Report, published Wednesday, September 2, put private-sector employment up 38,000 jobs in August, below the consensus estimate of about 48,000 and the slowest month since January. The July figure was revised up to 46,000.MACRO
  • The internals were split rather than uniformly weak. Education and health services added 45,000 positions, leisure and hospitality 16,000, construction 12,000 and financial activities 6,000, while manufacturing shed 17,000 and professional and business services lost 16,000.MACRO
  • On pay, ADP reported base pay up 3.2 percent and gross pay up 4.7 percent year over year for private-sector workers. A cooling hiring pace alongside pay growth near those levels is the combination that keeps the argument over the policy path unresolved.MACRO
  • The official August employment report lands Friday, September 4. ADP is a private estimate and has diverged from the government series before, so it sets the tone for the week rather than settling it.CALENDAR
RATES: A NEW HIGH, AND A FED OFFICIAL SAYING IT IS FINE×
  • The benchmark ten-year Treasury yield reached a session high of 4.814 percent on September 2 according to market data providers, a fifth leg higher in a move that has now run through several sessions. Yields also rose in the United Kingdom, Germany and France.RATES
  • How far back that level reaches depends on the provider. Coverage on September 2 described it as the highest since November 2023, while the reading carried on September 1 placed the comparison at January 2025. The level is consistent across sources, the historical comparison is not, and it is left as a discrepancy here rather than resolved into a third claim.RATES
  • New York Federal Reserve President John Williams said on Wednesday that the recent surge in Treasury yields reflects a strong economy rather than market dysfunction. He added that he is still absorbing the data and did not commit on whether a rate increase is warranted.RATES
  • The long-duration bond fund $TLT settled at 81.87 on September 1 against 82.34 on August 31, a decline of 0.57 percent, on Marketstack closes. No settled level for September 2 is available at the time of writing.RATES
ENERGY: THE HORMUZ PREMIUM HOLDS×
  • Brent traded around 95 dollars a barrel on Wednesday, close to its highest level in nearly six weeks. One market data provider quoted 94.86 dollars, up 0.23 percent on the day. West Texas Intermediate extended gains after topping 90 dollars in the previous session.ENERGY
  • The driver is unchanged and it is military rather than economic. United States forces struck Iranian targets around the Strait of Hormuz, described by the American administration as retaliation for attempts to lay mines in the waterway and for an earlier attack on a United States base. Iran said it had responded against United States bases in the region and fired missiles toward Jordan.ENERGY
  • The barrel is up roughly 13 percent over the past month on the same provider’s series. A move of that size in a single input feeds through to headline inflation expectations before it feeds through to anything else, which is the mechanism connecting a shipping lane to a Treasury auction.ENERGY
  • On settled Marketstack closes for September 1, the oil fund $USO ended at 141.00, up 5.46 percent on the session, and $XLE at 64.77 against 63.96 on August 31.ENERGY
AI HARDWARE: DELL RAISES ITS OWN NUMBERS×
  • Dell Technologies lifted its full-year revenue guidance by 25 billion dollars to 192 billion and raised its artificial intelligence server revenue target by 14 billion dollars to 74 billion, alongside a record artificial intelligence server backlog of 95 billion dollars. The results were released after the close on Tuesday, September 1.TECH
  • The share reaction on September 2 is reported inconsistently across sources, with intraday moves quoted between roughly 4.7 percent and 9 percent. The guidance figures are company-stated and firm; the intraday percentage is not reconciled here and no single number is asserted.TECH
  • The read-through moved down the supply chain on the same coverage: Hewlett Packard Enterprise was up around 4 percent and Super Micro Computer modestly higher. A raised order book from a server assembler is a demand signal for the components rather than for the assembler alone.TECH
  • Context from the previous settlement: $NVDA closed at 217.44 on September 1, down 1.51 percent, and $SMH at 545.22, down 2.10 percent, on Marketstack closes. Those declines came before Wednesday’s guidance news.TECH
BIOTECH: THE SEPTEMBER REGULATORY WINDOW×
  • No Food and Drug Administration action or late-stage readout in the Merlintrader coverage universe was confirmed against a primary source as having occurred on September 2, 2026. That is a statement about what could be verified for this edition, not a claim that nothing happened.BIOTECH
  • The dated item on the September calendar reported by specialist coverage is Scholar Rock’s apitegromab, a myostatin inhibitor proposed for spinal muscular atrophy, with a target action date of September 30, 2026. The date is carried by regulatory calendar coverage and was not read off an agency document for this edition.BIOTECH
  • Two further target action dates sit beyond the month on the same coverage: Vertex Pharmaceuticals’ povetacicept in IgA nephropathy on November 30, 2026, and BridgeBio Pharma’s BBP-418, accepted for Priority Review, on November 27, 2026.BIOTECH
  • On the negative side of the ledger, BioNTech and Genentech halted a personalised messenger RNA cancer vaccine trial after additional deaths in the treatment arm in immune-cold colorectal tumours. The date of the halt was not established for this edition.BIOTECH
SPACE, DEFENSE AND COMPUTE×
  • SpaceX is reported to be in discussions with the United States Department of Defense over a multibillion-dollar arrangement to supply artificial intelligence data centre capacity for Pentagon workloads. The report describes talks, not a signed contract, and the company is private.DEFENSE
  • The item matters to the listed names because it prices compute capacity as defense procurement rather than as cloud spending. If that framing holds, the buyer of last resort for orbital and terrestrial capacity changes, and so does the counterparty risk attached to it.DEFENSE
  • The last settled Marketstack closes in the group, dated September 1, were $ASTS at 55.80, $RKLB at 62.54, $OKLO at 38.53 and $PLTR at 179.92, all lower on that session. No settled September 2 level exists yet.WATCHLIST
THE REST OF THE WEEK×
  • The services activity survey follows on Thursday, September 3, and the August employment report on Friday, September 4 at 8:30 New York time. The Federal Open Market Committee meets on September 15 and 16.CALENDAR
  • Weekly jobless claims arrive Thursday alongside the services print. In a tape driven by the discount rate rather than by earnings, Friday’s payroll number carries more capacity to change the picture than anything else on the calendar.CALENDAR
BOTTOM LINE×
  • An index that stops falling while the barrel and the long yield keep rising is not the same thing as a resolved market. What changed on September 2 was a single company raising its own forecast and a Federal Reserve official putting a benign reading on the yield move, and both are narrative rather than settlement.BOTTOM LINE
  • Stated for the record and not verified against primary documents in this edition: all September 2 index, share and commodity levels, which are intraday readings from market data providers and wire coverage rather than settlements, since the New York session was open at the time of writing and Marketstack carried no September 2 settlement; the historical comparison attached to the ten-year yield, on which sources disagree; the intraday move in Dell shares, quoted differently across sources; the September 2 closing levels for the European indices, which could not be confirmed and are therefore not reported; and the regulatory target action dates, which come from calendar coverage rather than agency filings.BOTTOM LINE
  • This briefing is educational and informational content. It is not investment advice, an offer, or a recommendation to buy or sell any security. Readers should do their own research and consult an authorised financial adviser before making any investment decision.DISCLAIMER
Read the full Daily BriefingRead the Weekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: September 2 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when a material result or regulatory action still needs one continuity update. October and later events are excluded from this widget.

28On board
11FDA / Reg
17Data / Filing
Sep 2Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXP KETAFREE Ongoing FDA review First-cycle review complete; manufacturer vial attestation submitted

NRx Pharmaceuticals. The July 29 GDUFA goal date has passed, but the ANDA remains active. On August 7 the company reported that FDA had completed its first-cycle review of the preservative-free intravenous ketamine ANDA with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC or other drug-related review matters. The sole remaining major deficiency involved the container-closure system and a manufacturer attestation concerning the luer-lock vial. The same vial is used in three approved ANDA products that collectively shipped 11.9 million units in the United States over the prior 12 months, and the filing included testing of more than 3,500 vials from seven lots without observed luer-lock failures. On August 17 NRx confirmed that the requested attestation had been submitted. No company release has followed since August 17 and no new exact action date has been disclosed.

$PTGX MIMRYLO / rusfertide Aug 28 Approved FDA approval of the first hepcidin mimetic for polycythemia vera

Protagonist / Takeda. On August 28, 2026, the FDA approved MIMRYLO (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera. The once-weekly subcutaneous medicine is the first approved hepcidin mimetic. Approval is supported by the Phase 3 VERIFY trial, in which 76.9% of patients achieved the prespecified clinical response during weeks 20–32. The most common adverse reactions occurring in more than 15% of patients were injection-site reactions and anaemia. Protagonist discovered MIMRYLO and led development through Phase 3; Takeda holds exclusive global development and commercialisation rights.

$TLX Pixclara Sep 11 PDUFA FDA decision on the resubmitted Pixclara NDA

Telix Pharmaceuticals. September 11, 2026 is the FDA goal date for the resubmitted Pixclara (TLX101-Px) NDA, reconfirmed by the company in the half-year announcement filed on Form 6-K on August 20, 2026. The application was resubmitted in March and accepted in April, so the September catalyst is the decision on that NDA, not the filing itself. Pixclara is a PET imaging agent intended to help characterise suspected recurrent or progressive glioma against treatment-related changes. In the same document Telix confirmed that the Zircaix BLA has still to be resubmitted.

$RARE UX111 Sep 19 BLA Gene therapy for Sanfilippo syndrome type A

Ultragenyx. PDUFA for the resubmitted UX111 (rebisufligene etisparvovec) BLA in Sanfilippo syndrome type A, seeking accelerated approval. The date was set with the acceptance of the BLA resubmission and the company reaffirmed it in its August 4 update; no extension has been announced since. The August 19 accelerated approval of GENGLYCOS in glycogen storage disease type Ia is a separate programme and does not change this review.

$MRK WINREVAIR Sep 21 sBLA PAH · HYPERION-based label update

Merck. PDUFA for a supplemental BLA seeking a U.S. label update for WINREVAIR (sotatercept-csrk) based on the Phase 3 HYPERION study in pulmonary arterial hypertension. The September 21 date is stated in the Form 10-Q filed on August 7, 2026, and nothing published since changes it.

$IONS zilganersen Sep 22 NDA Alexander disease · Priority Review

Ionis. Priority Review PDUFA for the zilganersen NDA in Alexander disease, a rare progressive neurological disorder. The date is confirmed in the Form 10-Q filed on July 29, 2026. Ionis is preparing to commercialise the product itself in the United States, while ex-U.S. rights were licensed to Recordati in June 2026. It remains one of September’s most closely watched rare-disease decisions.

$GRAL Galleri Sep 23 FDA panel AdCom on the multi-cancer MCED test PMA

GRAIL. FDA’s Molecular and Clinical Genetics Panel is scheduled to meet on September 23, 2026 to discuss and vote on the Galleri premarket approval application. The meeting notice was published in the Federal Register on August 10, 2026, the session runs from 9:00 to 18:00 Eastern at White Oak in hybrid form, and public comments close on September 8. The FDA advisory committee calendar still carries the meeting with no postponement note. Galleri is a blood-based multi-cancer early detection test proposed for adults aged 50 and older; this is a device and diagnostics catalyst rather than a drug PDUFA, and it is the first FDA advisory committee ever convened on an MCED test.

$MIRM zilurgisertib Sep 26 NDA FOP · NDA rests on secondary endpoints

Mirum Pharmaceuticals / Incyte. Priority Review PDUFA for the zilurgisertib NDA in fibrodysplasia ossificans progressiva in patients aged 12 and older; the application is Incyte’s and Mirum holds exclusive worldwide rights under a licence signed in April 2026, with 25 million dollars due on FDA approval. The date is confirmed in Mirum’s Form 10-Q of August 5, 2026. The same filing states in its risk factors that “while the NDA for zilurgisertib is supported by secondary endpoints, the pivotal study did not reach statistical significance on the primary endpoint”. That pivotal study is the Phase 2 PROGRESS trial, whose results the company presented at ENDO 2026 without addressing the primary endpoint.

$BFRI Ameluz PDT Sep 28 sNDA Expansion into superficial basal cell carcinoma

Biofrontera. PDUFA for the Ameluz photodynamic-therapy sNDA in superficial basal cell carcinoma. The date comes from the filing-acceptance release of February 11, 2026, in which FDA identified no filing deficiencies, and the company reaffirmed a late-September action date in its second-quarter release of August 13, 2026, pointing to a launch in the first quarter of 2027. No filing or release has followed since.

$SRRK apitegromab Sep 30 BLA SMA · Catalent Indiana removed from the BLA on August 21

Scholar Rock. The apitegromab BLA in spinal muscular atrophy remains targeted to September 30. On August 21, 2026 the company said it had successfully removed Catalent Indiana as a commercial fill-finish facility from the BLA under FDA guidance, after Catalent notified customers on August 7 that its April inspection had been classified Official Action Indicated. In the same August 21 update Scholar Rock confirmed the action date as unchanged, said the European marketing authorisation application had been withdrawn following the CHMP written procedure of August 20 and would be resubmitted with the alternative site, and pointed to a Japanese filing by the end of 2026. Manufacturing and CMC risk therefore stays central to this review.

$ROIV LISRAYA / brepocitinib Aug 27 Approved FDA approval of the first targeted therapy for adult dermatomyositis

Roivant / Priovant. On August 27, 2026, the FDA approved LISRAYA (brepocitinib) 30 mg once daily for adults with dermatomyositis. It is the first targeted therapy approved for the disease and was available in the United States immediately. In the Phase 3 VALOR trial, 55% of patients achieved moderate-or-better improvement together with minimal or no steroid use at week 52, compared with 30% on placebo. The label carries a boxed warning covering serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis.

$QURE AMT-130 Q3 BLA Huntington’s disease · filing plus four-year data in September

uniQure. The AMT-130 accelerated-approval BLA in Huntington’s disease was still to be filed as of August 25; the July 29, 2026 quarterly update describes U.S. and U.K. submissions as on track for the third quarter. Official minutes of the Type B meeting received in July confirm alignment on a filing based on existing clinical data with comparison to an external control, while the design of the confirmatory study was still being discussed. Topline four-year data from the Phase I/II study are expected in September 2026, which makes the quarter dense for this programme.

$IMMX NXC-201 Late Sep Data NEXICART-2 · AL amyloidosis

Immix Biopharma. The next NEXICART-2 update for NXC-201 in relapsed or refractory AL amyloidosis is expected in late September 2026, a window stated in the company release of May 21, 2026. Enrolment of 45 patients is complete, as confirmed in the Form 10-Q of August 7, 2026, and one-year follow-up data due by the end of March 2027 are expected to guide the BLA. The programme is designed to be registrational.

$KPTI selinexor + ruxolitinib Aug 31 sNDA filed Accelerated-approval filing submitted; Priority Review requested

Karyopharm. On August 31, 2026, the company submitted an sNDA seeking accelerated approval of XPOVIO (selinexor) plus ruxolitinib in myelofibrosis and requested Priority Review. The application is based on the Phase 3 SENTRY programme, including the spleen-volume response data and longer-term overall-survival follow-up intended to verify clinical benefit. FDA filing acceptance and the formal review timetable are now the next regulatory events; no PDUFA date has yet been assigned.

$KOD DAYBREAK Sep Phase 3 Wet AMD · Zenkuda and KSI-501 against aflibercept

Kodiak Sciences. One-year primary-endpoint topline results from the Phase 3 DAYBREAK study in wet age-related macular degeneration are expected in September 2026, a guidance restated in the second-quarter release of August 13, 2026. The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 in parallel arms against aflibercept, and enrolment is complete. Cash stood at 125.9 million dollars at June 30 with runway stated into 2027, which raises the stakes on the readout.

$ALMS envudeucitinib / LUMUS Sep 1 Data reported Phase 2b LUMUS missed its primary and secondary endpoints overall

Alumis. The Phase 2b LUMUS trial in moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall population. The company reported robust responses in the prespecified high-interferon-gene-signature subgroup and plans to discuss a Phase 3 path with FDA and EMA. Envudeucitinib was generally well tolerated with no new safety signals. This result is separate from the psoriasis programme, for which an NDA submission remains guided to the fourth quarter of 2026.

$NVS remibrutinib / REMODEL Sep 1 Phase 3 data Both REMODEL trials met the primary endpoint in relapsing MS

Novartis. REMODEL-1 and REMODEL-2 met their primary endpoint, with oral remibrutinib significantly reducing annualised relapse rates versus teriflunomide in relapsing multiple sclerosis. The trials also showed superiority on key MRI secondary endpoints and a favourable safety profile with no liver safety signal. Novartis reported a positive trend on three-month confirmed disability progression and nominal significance on six-month progression in the prespecified pooled analysis. Detailed late-breaking data are due at MSToronto2026, after which the company plans global regulatory submissions.

$IVVD VYD2311 / DECLARATION + LIBERTY End Q3 Data / filing path Topline remains due around quarter-end; the regulatory route is not yet selected

Invivyd. DECLARATION and LIBERTY are approaching completion, with topline data still expected around the end of the third quarter. The company is evaluating two possible regulatory paths after discussions with FDA: full unblinding followed by a traditional BLA, or partial unblinding followed by an accelerated-approval BLA based on antiviral activity and safety. Invivyd has not yet selected a route, and there is no public FDA confirmation that either path has been accepted. The company said further updates are expected within weeks.

$PHVS deucrictibant XR Q3 Phase 3 CHAPTER-3 · hereditary angioedema prophylaxis

Pharvaris. Phase 3 CHAPTER-3 topline data for extended-release deucrictibant in hereditary-angioedema prophylaxis are expected in the third quarter of 2026, confirmed in the Form 6-K release of August 12, 2026, which puts randomisation at 85 participants assigned two to one to 40 mg daily or placebo over 24 weeks. It is one of the quarter’s most important registrational HAE readouts. Separately, the immediate-release NDA carries a PDUFA date of April 23, 2027.

$SYRE SPY003 Sep Data SKYLINE Part A in ulcerative colitis

Spyre Therapeutics. SPY003 Part A topline data from the Phase 2 SKYLINE study are expected in September 2026, as stated in the second-quarter release of August 4, 2026; enrolment of Part A is complete and SPY003 is the last of the three readouts, after SPY001 and SPY002 in April and June. The RA sub-study of SKYWAY is guided to the same month. With 1.145 billion dollars in cash and runway into the second half of 2029, financing risk is not the issue here.

$VERA TRUTAKNA / atacicept Q3 eGFR ORIGIN 3 final efficacy analysis

Vera Therapeutics. The ORIGIN 3 final efficacy analysis is expected in the third quarter, as restated in the second-quarter release of August 10, 2026. It follows the accelerated approval of TRUTAKNA (atacicept-vymj) on July 7, 2026, which rested on proteinuria, while ORIGIN 3 continues blinded and placebo-controlled with eGFR as the confirmatory endpoint. The timing was pulled forward from 2027 after alignment with FDA announced on June 2, 2026, and a supplemental BLA is guided to the fourth quarter. This is not another approval decision: what matters is the durability of the renal effect and the read-through for the confirmatory pathway.

$XENE azetukalner Q3 NDA Focal-onset seizure filing after the pre-NDA meeting

Xenon. The azetukalner NDA submission in focal-onset seizures is on track for the third quarter following the pre-NDA meeting with FDA, as stated in the second-quarter release of August 6, 2026. The application had not been filed as of August 25. Filing confirmation would open FDA’s filing-review stage and set up a later PDUFA assignment.

$BBIO infigratinib Aug 10 NDA submitted Achondroplasia · FDA filing acceptance is the next step

BridgeBio. BridgeBio confirmed on August 10, 2026 that it had submitted the NDA for oral infigratinib in achondroplasia, and its own pipeline table lists the next milestone as FDA setting a PDUFA date. Neither filing acceptance nor a PDUFA date had been announced as of August 25, so the programme stays on the board with the regulatory process materially open. Infigratinib holds Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations, U.S. launch is guided to mid-2027 and a European application is planned for the fourth quarter.

$MLTX sonelokimab Late Sep BLA Hidradenitis suppurativa filing after positive IZAR-1

MoonLake. The sonelokimab BLA in hidradenitis suppurativa is expected around the end of September 2026, with the company guiding to a PDUFA date allocation and a decision on Priority Review by the end of November. The milestone table sits in the August 10, 2026 release that also carried positive topline results from the Phase 3 IZAR-1 trial. The filing had not been announced as of August 25.

$BNTX gotistobart / pumitamig Sep 14–15 WCLC data PRESERVE-003 OS update and first pumitamig/ADC combination data

BioNTech. Two distinct WCLC 2026 readouts are on the board. On September 14, a mini-oral presentation (MO07.04) will report updated overall survival from stage 1 of the Phase 3 PRESERVE-003 trial of gotistobart versus docetaxel in advanced squamous NSCLC after PD-(L)1 progression. On September 15, a late-breaking oral presentation (OA14.01) will provide the first lung-cancer data for pumitamig combined with the B7H3-targeted ADC elfetabart drozuntecan. These are separate assets and studies, not one combined Phase 3 event.

$SMMT ivonescimab / HARMONi Sep 15 WCLC data Detailed updated overall-survival follow-up before the November PDUFA

Summit Therapeutics. Additional detail from the June 2026 overall-survival update in the global Phase 3 HARMONi trial will be presented at WCLC on September 15, 2026, at 13:02–13:12 KST in session OA14, abstract OA14.05. Summit previously reported an overall-survival hazard ratio of 0.76 in both the intention-to-treat population and western subgroup at the June cut-off, without publishing the full statistical package. The presentation lands two months before the November 14 PDUFA goal date for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after third-generation TKI progression.

$RGNX RGX-202 · Duchenne Q3 BLA Duchenne BLA submission still guided to this quarter, after the RGX-121 hold

REGENXBIO. On August 24, 2026 the FDA placed a clinical hold on the Phase I/II/III trial of RGX-121 in mucopolysaccharidosis type II, following asymptomatic spine MRI findings in five participants of the CAMPSIITE study, and the company said it does not expect to resubmit the RGX-121 Biologics License Application in the near term. In the same release it stated that the Duchenne and retinal programmes use a different capsid and different routes of administration, and that their near-term catalysts are on track: the planned submission of the Duchenne BLA this quarter, and wet AMD topline pivotal data in the fourth quarter. Investigators deemed the spine findings non-serious and radiologists believe they are likely benign; no brain nodules or masses were identified. The stock fell sharply on the hold, which makes the Duchenne filing the near-term item that either confirms or undermines the company’s separation of the two programmes.

$GOSS seralutinib Sep NDA PAH filing tied to a 125 million dollar financing tranche

Gossamer Bio. On August 21, 2026 the company said it expects to submit the seralutinib NDA in pulmonary arterial hypertension in September 2026. The filing carries a direct financial consequence: the 250 million dollar private placement announced alongside it is structured so that a second tranche of roughly 125 million dollars unlocks on FDA acceptance of the application within 2026. Submission and acceptance are therefore two distinct events to track.

Most attention-worthy watchlist

$NRXP$RARE$IONS$GRAL$MIRM$SRRK$PHVS$QURE$IMMX$KPTI$VERA

Board rule

Only future or still materially unresolved catalysts through September are shown; newly resolved events remain for one continuity update. $PTGX/MIMRYLO is corrected from an open August window to FDA approval on August 28. $ROIV/LISRAYA is corrected from an unresolved Q3 window to FDA approval on August 27. $KPTI is corrected from a planned August filing to an sNDA submitted on August 31, with Priority Review requested; filing acceptance and the formal review timetable remain open. $ALMS/LUMUS is updated to the September 1 result: the trial missed its primary and secondary endpoints overall, while the prespecified IFNGS-high subgroup supports further regulatory discussion. $IVVD now reflects the two possible BLA paths disclosed on September 1 without presenting either as already accepted by FDA. $NVS/remibrutinib joins after both REMODEL Phase 3 trials met their primary endpoint on September 1. $BNTX now separates the September 14 gotistobart update from the September 15 pumitamig combination data, and $SMMT carries the corrected WCLC abstract number OA14.05. $JAZZ and $GILD roll off after their completed approvals aged beyond the brief continuity window. Month-only and quarter-only windows remain company guidance, not exact FDA or readout dates.

Educational content only — not investment advice or a recommendation to buy or sell securities. Verify dates and primary filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.